PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Technische Universität München

27.04.2020 – 14:01

Technische Universität München

In the hunt for new treatments against the coronavirus

TECHNICAL UNIVERSITY OF MUNICH

Corporate Communications Center

phone: +49 8161/ 71-3207 - e-mail: presse@tum.de - web: www.tum.de

This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35999/

High resolution images: https://mediatum.ub.tum.de/1544195

In the hunt for new treatments against the coronavirus

Researchers develop software for drug repurposing

Currently, the corona pandemic is dominating the entire social life in Germany and in many other parts of the world. We are working flat out in order to better help the more than one hundred thousand seriously ill people in hospitals. One promising approach to extending current treatment methods is to use existing and approved drugs to combat the virus.

In order to find out which existing drugs might be suitable for the treatment of Covid-19, numerous research groups from all over the world are working on systems medicine approaches. A research team from the Chair of Experimental Bioinformatics (ExBio) at the TUM School of Life Sciences of the Technical University of Munich (TUM) has now developed the first online data analysis platform for this purpose.

Systems Medicine and Artificial Intelligence for data analysis

The so-called Coronavirus Explorer (CoVex) integrates the virus-human interactome for SARS-CoV-2 and SARS-CoV. CoVex is designed to help provide a comprehensive understanding of the infection mechanisms and focuses not only on the virus and its direct interaction partners, but in particular involves the host-protein interaction network.

"The goal of CoVex is to make data more accessible and analyzable with the help of Artificial Intelligence, even for non-computer scientists such as virologists. The virus-host interactome of SARS-CoV-2 serves as the basis for our systems medicine approach," explains Prof. Jan Baumbach, head of the Department of Experimental Bioinformatics.

Identification of drug repurposing candidates for treatment of Covid-19

"In particular, candidates for the reuse of known active substances are to be identified using CoVex. These do not target - as most of the existing drugs - directly the proteins of the virus, but against interaction partners in human cells. This makes it more difficult for the virus to escape treatment by mutating its own genome. This can be of great importance in possible future epidemic waves," said Baumbach.

"Our network-based approach can significantly accelerate the identification of potential drugs for the treatment of COVID-19," said Prof. Baumbach.

Data analysis platform publicly available

CoVex is therefore available to biological, medical and computer-based researchers as well as to the general public. Users can already view the latest available molecular data on SARS-CoV-2 and perform systems medicine analyses at https://exbio.wzw.tum.de/covex/.

However, Prof. Baumbach emphasizes that CoVex is a method for predicting possible future drugs for COVID-19, which have not yet undergone more intensive preclinical or clinical validation. "Under normal circumstances, we would not have gone public with CoVex at this point in time, but since the main functionality is implemented, we believe that this first version is already extremely useful for many researchers," said the chair holder.

In the coming weeks, CoVex will be continuously updated, for example by incorporating the latest experimental data for SARS-CoV-2 and implementing new functionalities. Furthermore, predicted candidates for new COVID-19 drugs will be pre-clinically tested and investigated.

More information:

A short video introduction into SARS-CoV-2 systems medicine and how CoVex works is available here.

CoVex was developed in a ca. 10-day hackaton project at the Chair of Experimental Bioinformatics at the Technical University of Munich in Germany. The tool is publicly available and free to be used. It's development and functionalities and decision-making is documented in public blogs:

https://www.exbio.de/exbio-vs-covid-part-1

https://www.exbio.de/exbio-vs-covid-part-2

Images for journalists: https://mediatum.ub.tum.de/1544195

Contact:

Prof. Dr. Jan Baumbach

Technical University of Munich

Chair of Experimental Bioinformatics

TUM School of Life Sciences

Tel.: +49-8161-71-2136

e-mail: exbio@wzw.tum.de

The Technical University of Munich (TUM) is one of Europe’s leading research universities, with around 600 professors, 43,000 students, and 10,000 academic and non-academic staff. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, combined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with the TUM Asia campus in Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006, 2012, and 2019 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany.

More stories: Technische Universität München
More stories: Technische Universität München